CA2542967A1 - Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives - Google Patents

Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives Download PDF

Info

Publication number
CA2542967A1
CA2542967A1 CA002542967A CA2542967A CA2542967A1 CA 2542967 A1 CA2542967 A1 CA 2542967A1 CA 002542967 A CA002542967 A CA 002542967A CA 2542967 A CA2542967 A CA 2542967A CA 2542967 A1 CA2542967 A1 CA 2542967A1
Authority
CA
Canada
Prior art keywords
compound
formula
ethyl
methyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002542967A
Other languages
English (en)
French (fr)
Inventor
Aesop Cho
Thorsten A. Kirschberg
Will Watkins
Maria Fardis
Lee S. Chong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/013121 external-priority patent/WO2004096235A2/en
Priority claimed from PCT/US2004/013198 external-priority patent/WO2004100960A2/en
Priority claimed from PCT/US2004/013143 external-priority patent/WO2004096236A2/en
Priority claimed from PCT/US2004/013063 external-priority patent/WO2004096286A2/en
Priority claimed from PCT/US2004/013064 external-priority patent/WO2004096287A2/en
Application filed by Individual filed Critical Individual
Publication of CA2542967A1 publication Critical patent/CA2542967A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002542967A 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives Abandoned CA2542967A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US51425803P 2003-10-24 2003-10-24
US60/514,258 2003-10-24
PCT/US2004/013121 WO2004096235A2 (en) 2003-04-25 2004-04-26 Anti-cancer phosphonate analogs
USPCT/US04/013064 2004-04-26
USPCT/US04/013063 2004-04-26
PCT/US2004/013198 WO2004100960A2 (en) 2003-04-25 2004-04-26 Anti-inflammatory phosphonate compounds
PCT/US2004/013143 WO2004096236A2 (en) 2003-04-25 2004-04-26 Immunomodulator phosphonate conjugates
USPCT/US04/013143 2004-04-26
PCT/US2004/013063 WO2004096286A2 (en) 2003-04-25 2004-04-26 Antiviral phosphonate analogs
USPCT/US04/013198 2004-04-26
USPCT/US04/013121 2004-04-26
PCT/US2004/013064 WO2004096287A2 (en) 2003-04-25 2004-04-26 Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
PCT/US2004/035136 WO2005039552A2 (en) 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives

Publications (1)

Publication Number Publication Date
CA2542967A1 true CA2542967A1 (en) 2005-05-06

Family

ID=38344791

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002542967A Abandoned CA2542967A1 (en) 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives

Country Status (7)

Country Link
US (1) US20070027116A1 (US07794700-20100914-C00152.png)
EP (1) EP1680129A2 (US07794700-20100914-C00152.png)
JP (1) JP2007520452A (US07794700-20100914-C00152.png)
CN (1) CN101410120A (US07794700-20100914-C00152.png)
AU (1) AU2004283710A1 (US07794700-20100914-C00152.png)
CA (1) CA2542967A1 (US07794700-20100914-C00152.png)
WO (1) WO2005039552A2 (US07794700-20100914-C00152.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7683188B2 (en) 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
PT1778251E (pt) 2004-07-27 2011-06-29 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores de vih
JP2009502964A (ja) * 2005-07-27 2009-01-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを阻害するための抗ウイルス性ホスホン酸結合体
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
CA2729769C (en) 2008-07-08 2017-09-05 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
BRPI1009324A2 (pt) * 2009-03-20 2015-11-24 Alios Biopharma Inc compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
WO2010120388A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8530492B2 (en) * 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
CN106565769B (zh) * 2016-11-12 2018-12-04 北京汇康博源医药科技有限公司 恩替卡韦中间体的合成工艺
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN110726801A (zh) * 2019-10-31 2020-01-24 山东泰星新材料股份有限公司 一种监测烷基次膦酸反应状态的方法
IT202100005777A1 (it) 2021-03-11 2022-09-11 Hippocrates Res S R L Composizione per l’uso nel trattamento dell’occhio secco

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5610294A (en) * 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
EP0708760A1 (en) * 1993-07-14 1996-05-01 Novartis AG Cyclic hydrazine compounds
US5446137B1 (en) * 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5493030A (en) * 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
CA2261619C (en) * 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6174888B1 (en) * 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
TNSN00027A1 (fr) * 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease
US6258831B1 (en) * 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
JP4773010B2 (ja) * 1999-06-25 2011-09-14 バーテックス ファーマシューティカルズ インコーポレイテッド Impdhのカーバメート阻害剤のプロドラッグ
WO2001064693A1 (fr) * 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Compose de nucleotide de phosphonate
DK2682397T3 (da) * 2000-07-21 2017-06-19 Gilead Sciences Inc Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
KR20020097384A (ko) * 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
KR100987815B1 (ko) * 2002-04-26 2010-10-18 길리애드 사이언시즈, 인코포레이티드 Hiv 프로테아제 억제제 화합물의 포스포네이트유사체의 세포 축적
WO2005011709A1 (en) * 2003-02-19 2005-02-10 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections

Also Published As

Publication number Publication date
JP2007520452A (ja) 2007-07-26
US20070027116A1 (en) 2007-02-01
AU2004283710A1 (en) 2005-05-06
EP1680129A2 (en) 2006-07-19
WO2005039552A3 (en) 2005-06-09
CN101410120A (zh) 2009-04-15
WO2005039552A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
AU2005267800B2 (en) Nucleoside phosphonate conjugates as anti HIV agents
CA2523083C (en) Antiviral phosphonate analogs
EP1907403B1 (en) Antiviral compounds
EP1778702B1 (en) Antiviral compounds
CA2542967A1 (en) Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives
CA2548951A1 (en) Kinase inhibitor phosphonate conjugates
CA2481285A1 (en) Non nucleoside reverse transcriptase inhibitors
AU2006270264A1 (en) Antiviral compounds
AU2006272521A1 (en) Antiviral phosphonate conjugates for inhibition of HIV
CA2522845A1 (en) Kinase inhibitor phosphonate conjugates
US7427636B2 (en) Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
CA2533966A1 (en) Nucleobase phosphonate analogs for antiviral treatment
AU2005299284A1 (en) Phosphonate derivatives of mycophenolic acid
WO2005044308A1 (en) Phosphonate analogs of antimetabolites
NZ542343A (en) Immunomodulator phosphonate conjugates
AU2011218664B2 (en) Antiviral compounds
AU2005299504A1 (en) Phosphonate substituted kinase inhibitors
BIRKUS et al. Patent 2481449 Summary
CA2523045A1 (en) Anti-inflammatory phosphonate compounds
CA2522977A1 (en) Immunomodulator phosphonate conjugates

Legal Events

Date Code Title Description
FZDE Discontinued